No Data
Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Express News | Esperion Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Esperion Therapeutics Exec Sells Over $4,600 in Stock
Why Is Esperion Therapeutics (ESPR) Down 3.9% Since Last Earnings Report?
JMP Securities Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $7
Express News | Esperion Secures Additional Commercial and Medicare Formulary Coverage for Nexletol® (Bempedoic Acid) and Nexlizet® (Bempedoic Acid and Ezetimibe)
ひな☆彡 SOXL : You convinced me. I am happy to buy some later.
Growth Investor27 : Long ESPR $1.61 is very cheap.
Growth Investor27 : Long150,000 will hold for 5x upside for 2025 if not aquired.